Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 282

1.

Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.

Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, van Rhee F, Fassas A, Crowley J, Tricot G, Barlogie B, Shaughnessy J Jr.

Blood. 2002 Mar 1;99(5):1745-57.

2.
3.

Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis.

Davies FE, Dring AM, Li C, Rawstron AC, Shammas MA, O'Connor SM, Fenton JA, Hideshima T, Chauhan D, Tai IT, Robinson E, Auclair D, Rees K, Gonzalez D, Ashcroft AJ, Dasgupta R, Mitsiades C, Mitsiades N, Chen LB, Wong WH, Munshi NC, Morgan GJ, Anderson KC.

Blood. 2003 Dec 15;102(13):4504-11. Epub 2003 Aug 28.

4.

Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells.

Mylin AK, Rasmussen T, Johansen JS, Knudsen LM, Nørgaard PH, Lenhoff S, Dahl IM, Johnsen HE; Nordic Myeloma Study Group.

Eur J Haematol. 2006 Nov;77(5):416-24. Epub 2006 Aug 23.

PMID:
16930142
5.

SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs.

Taylor BJ, Reiman T, Pittman JA, Keats JJ, de Bruijn DR, Mant MJ, Belch AR, Pilarski LM.

J Immunother. 2005 Nov-Dec;28(6):564-75.

PMID:
16224274
7.

Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma.

Mattioli M, Agnelli L, Fabris S, Baldini L, Morabito F, Bicciato S, Verdelli D, Intini D, Nobili L, Cro L, Pruneri G, Callea V, Stelitano C, Maiolo AT, Lombardi L, Neri A.

Oncogene. 2005 Apr 7;24(15):2461-73.

PMID:
15735737
8.

Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells.

Fagerli UM, Holt RU, Holien T, Vaatsveen TK, Zhan F, Egeberg KW, Barlogie B, Waage A, Aarset H, Dai HY, Shaughnessy JD Jr, Sundan A, Børset M.

Blood. 2008 Jan 15;111(2):806-15. Epub 2007 Oct 12.

9.

Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entities.

Rasmussen T, Theilgaard-Mönch K, Hudlebusch HR, Lodahl M, Johnsen HE, Dahl IM.

Br J Haematol. 2003 Oct;123(2):253-62.

PMID:
14531906
10.

Gene expression profiling of bone marrow endothelial cells in patients with multiple myeloma.

Ria R, Todoerti K, Berardi S, Coluccia AM, De Luisi A, Mattioli M, Ronchetti D, Morabito F, Guarini A, Petrucci MT, Dammacco F, Ribatti D, Neri A, Vacca A.

Clin Cancer Res. 2009 Sep 1;15(17):5369-78. doi: 10.1158/1078-0432.CCR-09-0040. Epub 2009 Aug 18.

11.

Identification of ID-1 as a potential target gene of MMSET in multiple myeloma.

Hudlebusch HR, Theilgaard-Mönch K, Lodahl M, Johnsen HE, Rasmussen T.

Br J Haematol. 2005 Sep;130(5):700-8.

PMID:
16115125
12.

Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.

Ocqueteau M, Orfao A, Almeida J, Bladé J, González M, García-Sanz R, López-Berges C, Moro MJ, Hernández J, Escribano L, Caballero D, Rozman M, San Miguel JF.

Am J Pathol. 1998 Jun;152(6):1655-65.

13.

Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance.

Skrtić A, Korać P, Krišto DR, Ajduković Stojisavljević R, Ivanković D, Dominis M.

Hum Pathol. 2010 Dec;41(12):1702-10. doi: 10.1016/j.humpath.2010.05.002. Epub 2010 Aug 30.

PMID:
20800871
14.

p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance.

Guillerm G, Gyan E, Wolowiec D, Facon T, Avet-Loiseau H, Kuliczkowski K, Bauters F, Fenaux P, Quesnel B.

Blood. 2001 Jul 1;98(1):244-6.

15.

Immunophenotypic and DNA content characteristics of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance.

Almeida J, Orfao A, Mateo G, Ocqueteau M, García-Sanz R, Moro MJ, Hernandez J, Ortega F, Borrego D, Barez A, Mejido M, San Miguel JF.

Pathol Biol (Paris). 1999 Feb;47(2):119-27. Review.

PMID:
10192879
16.

Identification of genes modulated in multiple myeloma using genetically identical twin samples.

Munshi NC, Hideshima T, Carrasco D, Shammas M, Auclair D, Davies F, Mitsiades N, Mitsiades C, Kim RS, Li C, Rajkumar SV, Fonseca R, Bergsagel L, Chauhan D, Anderson KC.

Blood. 2004 Mar 1;103(5):1799-806. Epub 2003 Sep 11.

17.

99mTc-sestamibi imaging and bone marrow karyotyping in the assessment of multiple myeloma and MGUS.

Giovanella L, Taborelli M, Ceriani L, Zucca E, Cavalli F, Delaloye AB.

Nucl Med Commun. 2008 Jun;29(6):535-41. doi: 10.1097/MNM.0b013e3282f5e5df.

PMID:
18458600
18.

Insights from the gene expression profiling of multiple myeloma.

Claudio JO, Masih-Khan E, Stewart AK.

Curr Hematol Rep. 2004 Jan;3(1):67-73. Review.

PMID:
14695854
19.

Genomic abnormalities in monoclonal gammopathy of undetermined significance.

Fonseca R, Bailey RJ, Ahmann GJ, Rajkumar SV, Hoyer JD, Lust JA, Kyle RA, Gertz MA, Greipp PR, Dewald GW.

Blood. 2002 Aug 15;100(4):1417-24.

20.

Cyclin D1 overexpression is not a specific grouping marker, but may collaborate with CDC37 in myeloma cells.

Katayama Y, Sakai A, Okikawa Y, Oue N, Asaoku H, Sasaki A, Imanaka F, Tsujimoto T, Takimoto Y, Masuda R, Nakaju N, Otsuki T, Yasui W, Kimura A.

Int J Oncol. 2004 Sep;25(3):579-95.

PMID:
15289859
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk